Product logins

Find logins to all Clarivate products below.


Hospital-Treated Gram-Negative Infections | Current Treatment: Physician Insights | US | 2024

Generic antibiotics continue to dominate the hospital-treated gram-negative infection (GNI) therapy market. Most inpatients are successfully treated empirically with such agents, and thus branded products like Allergan / AbbVie’s Avycaz, Shionogi’s Fetroja, Paratek Pharmaceuticals’ Nuzyra, Merck & Co.’s Recarbrio, Innoviva / Entasis’s Xacduro, Tetraphase Pharmaceuticals’ Xerava, Cipla Therapeutics’ Zemdri, and Merck & Co.’s Zerbaxa are typically restricted to later lines of therapy. Yet, increasing rates of antimicrobial resistance have created the need for safer products to effectively treat drug-resistant GNIs. In this analysis, we explore brand use in this market based on factors such as activity against key drug-resistant pathogens. Furthermore, hospital-based GNI specialists offer insight into how they treat GNIs in response to growing drug resistance.

QUESTIONS ANSWERED

  • What are the most prescribed first-, second-, and third-line therapies for inpatients with urinary tract infections, nosocomial pneumonia, or complicated intra-abdominal infections?
  • How are physicians approaching the treatment of infections caused by drug-resistant pathogens?
  • Which clinical and nonclinical factors drive, and limit, the prescribing of branded agents such as Avycaz, Zerbaxa, Zemdri, Xerava, and Nuzyra?
  • What will be the impact of recently approved agents such as Xacduro? What will drive use of such therapies, and in which infection types will they be used? Which current agents will be most affected?

PRODUCT DESCRIPTION Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.

CONTENT HIGHLIGHTS

Geography: United States

Primary research: Survey of 100 U.S. hospital-based infectious disease and critical care specialists

Key drugs covered: Avycaz, Fetroja, Nuzyra, Recarbrio, Xacduro, Xerava, Zemdri, Zerbaxa

Related Market Assessment Reports

Report
Eosinophilic Esophagitis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Eosinophilic Esophagitis (US)
Eosinophilic esophagitis (EoE) is a chronic allergic inflammatory condition of the esophagus, marked by an accumulation of eosinophils. This can lead to difficulty swallowing and potentially…
Report
Metabolic Dysfunction-Associated Steatohepatitis – Unmet Need – Unmet Need – Metabolic Dysfunction-Associated Steatohepatitis (US/EU)
Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), has the potential to be a large and lucrative therapy market owing to the disease…
Report
Human Immunodeficiency Virus – Landscape & Forecast – Disease Landscape & Forecast (G7)
The HIV therapy market is undergoing significant transformation, driven by innovative ARVs and evolving treatment strategies. The market is crowded with many approved ARVs, including STRs such as…
Report
Hepatocellular Carcinoma – Geographic Focus: China – Hepatocellular Carcinoma – China In-Depth (China)
The hepatocellular carcinoma therapy market in China is poised to experience significant growth, driven by an aging population and the high prevalence of hepatitis B and C infection. Angiogenesis…
Report
Multiple Myeloma – Geographic Focus: China – Multiple Myeloma – China In-Depth (China)
China’s multiple myeloma therapy market is evolving rapidly, driven by an increasing disease burden and advances in treatment options. Current therapies in China largely mirror global standards;…